Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
iNKT Cell Infusion for Tuberculosis with Malignant Solid Tumor
NCT03551795Phase 2Completed
- Start
- Jan 2018
- Primary completion
- Dec 2021
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial in malignant solid tumor and Tuberculosis (TB). Primary endpoint: Objective Response Rate at 4 months. Started Jan 2018; status: completed.
02
Conditions
malignant solid tumorTuberculosis (TB)
Beyond the preview
Go deeper on NCT03551795.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03551795.